LONDON May 2 Shire, the pharma group
that bought haemophilia specialist Baxalta last year, reported a
better-than-expected 14 percent rise in first-quarter earnings,
helped by higher sales of rare disease drugs and demand for its
new dry eye medicine.
The London-listed firm reported non-GAAP diluted earnings
per ADS of $3.63, beating analyst forecasts of $3.27, according
to Thomson Reuters I/B/E/S. Product sales, which were boosted by
the Baxalta deal, rose 110 percent to $3.4 billion.
The company reiterated its full-year forecast given in
February for product sales to rise to $14.5-14.8 billion this
year and earnings per share to increase to $14.60-$15.20.
(Reporting by Paul Sandle; editing by Kate Holton)